DelveInsight has launched a new report on Non Muscle Invasive Bladder Cancer Pipeline
Non-muscle invasive bladder cancer (NMIBC) formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence that often requires lifelong surveillance. The cancer is found in the tissue that lines the inner surface of the bladder wherein the bladder muscle is not involved.
Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight
Non Muscle Invasive Bladder Cancer Pipeline analysis across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of Non Muscle Invasive Bladder Cancer Pipeline products with detailed clinical profiles, key cross -competition, launch date along with product development activities.
Non Muscle Invasive Bladder Cancer Pipeline
The high-grade NMIBC pipeline possesses potential drugs in mid and late stage developments to be launched in the near future. The major key players include Viventia Bio/Sesen Bio (Vicinium), FKD Therapies Oy/Ferring Pharmaceuticals (Adstiladrin), CG Oncology (CG0070), ImmunityBio/Altor Biosciences (N-803 (ALT-803)), Theralase (TLD-1433), Merck (Keytruda) and others that hold the potential to create a significant positive shift in NMIBC in the market size.
Marketed drugs included in the report
- Keytruda (pembrolizumab): Merck
- Valstar (valrubicin): Endo Pharmaceuticals
Emerging drugs included in the report
- Vicinium: Sesen Bio
- Adstiladrin (nadofaragene firadenovec/Syn3): FKD Therapies Oy/ Ferring Pharmaceuticals
- Tecentriq (atezolizumab): Hoffmann-La Roche
- Sasanlimab (PF-06801591) + BCG: Pfizer
- And many others
Non Muscle Invasive Bladder Cancer Treatment
The main treatments when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, intravesical immunotherapy (BCG) andintravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases.
The market is expected to grow by factors like the expected entry of emerging therapies with novel targets and pricing. Furthermore, the upcoming products such as Adstiladrin, Vicinium, N-803, TLD-1433, CG0070 and Keytruda are anticipated to expand the market with a deeper penetration in the 7MM.
Non Muscle Invasive Bladder Cancer Symptoms
- Some people may have symptoms that suggest they have bladder cancer. Others may feel nothing at all. Some symptoms should never be ignored. Some of the common symptoms are:
- Hematuria (blood in the urine) - the most common symptom, often without pain
- Frequent and urgent urination
- Pain when urine passes
- Pain in lower abdomen
- Back pain
Non Muscle Invasive Bladder Cancer Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Non-muscle invasive bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Non-muscle invasive bladder cancer.
- In August 2018, Sesen Bio announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Vicinium for the treatment of BCG-unresponsive high-grade non-muscle invasive bladder cancer (NMIBC).
- The FDA granted Instiladrin, Breakthrough Therapy designation and its Biologics License Application (BLA) has been accepted for filing and granted Priority Review.
- In September 2019, Anchiano Therapeutics reported that it had entered into an exclusive worldwide collaboration and option to license agreement with ADT Pharmaceuticals to develop novel small-molecule inhibitors of RAS and PDE10/β-catenin. This collaboration reflects Anchiano’s ongoing strategy to grow a pipeline beyond its pivotal-stage asset, inodiftagene vixteplasmid, with programs that have the potential to address significant clinical needs, while leveraging Anchiano’s expertise in small-molecule oncology development.
- LiPax Platform is a proprietary proliposomal intracavitary paclitaxel drug delivery platform designed to enhance the therapeutic index of proven cancer drugs, which results in more effective treatments for intracavitary cancers. LIPAC’s lead drug candidate, LiPax, is a locally delivered formulation of the well-established chemotherapy drug, paclitaxel. It is in Phase 1/2a clinical trial for non-muscle invasive bladder cancer (NMIBC) and has demonstrated impressive initial clinical activity while being very well tolerated. LiPax is also in preclinical development for upper tract urothelial carcinoma (UTUC), ovarian cancer, intraperitoneal carcinoma, and mesothelioma/malignant pleural effusion.
Request for free sample copy- https://www.delveinsight.com/sample-request/non-muscle-invasive-bladder-cancer-pipeline-insight
Table of content
Introduction
Executive Summary
Non-muscle invasive bladder cancer: Overview
Pipeline Therapeutics
Therapeutic Assessment
Non-muscle invasive bladder cancer – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Non-muscle invasive bladder cancer Collaboration Deals
Late Stage Products
Vicinium : Sesen Bio
APL-1202: Asieris Pharmaceuticals
Mid Stage Products
UGN-102: UroGen Pharma
Balversa: Janssen Pharmaceuticals
Early Stage Products
UGN-201: UroGen Pharma
E7766: H3 Biomedicine
Pre-clinical and Discovery Stage Products
ATX 101: APIM Therapeutics
Inactive Products
Non Muscle Invasive Bladder Cancer Key Companies
Non Muscle Invasive Bladder Cancer Key Products
Non Muscle Invasive Bladder Cancer- Unmet Needs
Non Muscle Invasive Bladder Cancer- Market Drivers and Barriers
Non Muscle Invasive Bladder Cancer- Future Perspectives and Conclusion
Non Muscle Invasive Bladder Cancer Analyst Views
Non Muscle Invasive Bladder Cancer Key Companies
Appendix
Related Reports
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
